M&A / Deals

Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’

BioSpace

Weight loss giant Eli Lilly has penned a DNA editing deal with Profluent Bio, continuing its dealmaking spree as well as its commitment to artificial intelligence.

Gene Therapy

Read full story

pharminent April 28, 2026 (Last updated: April 28, 2026)

BioSpace

Weight loss giant Eli Lilly has penned a DNA editing deal with Profluent Bio, continuing its dealmaking spree as well as its commitment to artificial intelligence.

Gene Therapy

Read full story

Related Stories

Eli Lilly to buy trio of vaccine developers in $3.8bn outlay

Gilead inks $140M API supply deal, tightening ties to Korean manufacturer

GBL joins CVC in 10.7bn takeover bid for Recordati

You May Have Missed

Eli Lilly to buy trio of vaccine developers in $3.8bn outlay

Arthrosi drug trial in gout delivers for new owner Sobi

Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study

Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC